title: Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical context: a preliminary study using a multiplexing approach.
abstract: The present study was undertaken to validate a battery of cytotoxicity assays performed in a multiplex format to screen pharmaceutical compounds at an early stage of drug development. Two experiments were performed on HepG2 cells and the parameters were measured in 96-well plates. Biological and technical triplicates were performed to evaluate the reproducibility of the assay. In the first experiment, HepG2 cells were exposed to tamoxifen, staurosporine, phenobarbital and triton X-100 for 2 and 24h. The following nine cytotoxicity parameters were analyzed, cell viability, lactate dehydrogenase (LDH), adenosine triphosphate (ATP), caspase-3/7, aspartate aminotransferase (AST), glutamate dehydrogenase (GLDH), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and alpha-glutathione-S-transferase (alpha-GST). In the second experiment, HepG2 cells were exposed to doxorubicin, t-butyl hydroperoxide, ferrous sulfate and sulfamoxole for 2 and 24h. Based on the results of the first experiment, six cytotoxicity parameters were selected for further evaluation (cell viability, ATP, LDH, caspase, AST and GLDH). ALT (activity always below detection limit), ALP (no response to drug treatment) and alpha-GST (too labor intensive and not possible to multiplex) were eliminated. The analysis of the data revealed that the reproducibility of the assays was accurate according to principal component analysis. Our data also clearly indicated that the potential of this battery of selected assays measured in a multiplex format not only made it possible to rank and select the most promising drug candidates based on their cytotoxic potential, but also to gather information that may help to understand some of the toxic events occurring in the cells.
authors.affiliation: UCB Pharma SA, Investigative Non-Clinical Safety, Non-Clinical Development, Chemin du Foriest, 1420 Braine-l'Alleud, Belgium. Helga.Gerets@ucb-group.com
authors.forename: H H J
authors.initials: HH
authors.lastname: Gerets
authors.forename: E
authors.initials: E
authors.lastname: Hanon
authors.forename: M
authors.initials: M
authors.lastname: Cornet
authors.forename: S
authors.initials: S
authors.lastname: Dhalluin
authors.forename: O
authors.initials: O
authors.lastname: Depelchin
authors.forename: M
authors.initials: M
authors.lastname: Canning
authors.forename: F A
authors.initials: FA
authors.lastname: Atienzar
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D064420:Drug-Related Side Effects and Adverse Reactions; D004798:Enzymes / Q000378:metabolism; D022781:Hepatocytes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008403:Mass Screening / Q000379:methods; D004364:Pharmaceutical Preparations / Q000145:classification; D015203:Reproducibility of Results; D015262:Xenobiotics / Q000145:classification / Q000633:toxicity*
chemical_list: D015415:Biomarkers; D004798:Enzymes; D004364:Pharmaceutical Preparations; D015262:Xenobiotics; D000255:Adenosine Triphosphate